Risk assessment of CYP3A induction by ginsenoside’s metabolites from oral Panax notoginseng (sanqi) extract
- 22 April 2025
- journal article
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 349, 119864
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Technology of the People's Republic of China
- National Natural Science Foundation of China (82074273, 82192912)
This publication has 48 references indexed in Scilit:
- Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial InfarctionJAMA, 2023
- Effect of an Herbal-Based Injection on 28-Day Mortality in Patients With SepsisJAMA Internal Medicine, 2023
- Potential herb–drug interactions between anti-COVID-19 drugs and traditional Chinese medicineActa Pharmaceutica Sinica B, 2023
- Cardioprotection of Panax Notoginseng saponins against acute myocardial infarction and heart failure through inducing autophagyBiomedicine & Pharmacotherapy, 2021
- A microbial metabolite remodels the gut-liver axis following bariatric surgeryCell Host & Microbe, 2021
- Comparison of intramuscular and intravenous pharmacokinetics of ginsenosides in humans after dosing XueShuanTong, a lyophilized extract of Panax notoginseng rootsJournal of Ethnopharmacology, 2020
- High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing and antibiotics comedicated in sepsis careActa Pharmaceutica Sinica B, 2019
- Liver–Microbiome Axis in Health and DiseaseTrends in Immunology, 2018
- A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of the Effects of Qili Qiangxin Capsules in Patients With Chronic Heart FailureJACC, 2013
- Interaction of citrus juices with felodipine and nifedipineThe Lancet, 1991